Roche doubles down on its Alzheimer's ambitions as next-gen amyloid-lowering drug excites scientists

TORONTO — Three years after a disappointing clinical failure cast doubts on Roche’s future in Alzheimer’s disease, the company is going all in on a sequel program. And early data suggest it might be the ...